Nearly two decades ago, in a search for molecules that regulate cyclic GMP (cGMP) levels in the intestine, guanylin was identified as a low molecular weight, acid stable peptide present in rat jejunal extracts. A year later, uroguanylin was purified from opossum urine and was seen to exhibit a ten-fold higher bio-activity as compared to guanylin. Subsequently, guanylin and uroguanylin emerged as key players in intestinal fluid homeostasis, a phenomenon fundamental to the maintenance of gut physiology. Both these regulatory peptides are produced in the enteroendocrine cells of the intestinal mucosa as precursor proteins and are processed to their mature forms by converting enzymes. The biologically active forms of guanylin and uroguanylin have striking similarities in their structure, and contain four conserved cysteines which form disulfide linkages essential for their activity.
Guanylyl cyclase C (GC-C) is the receptor that is activated by these peptides. Owing to its apical localization in enterocytes, the extracellular domain of GC-C can bind uroguanylin/guanylin released into the gut lumen, initiating production of the intracellular second messenger, cGMP. Cyclic GMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) that serves as a membrane channel, modulating chloride efflux from the enterocytes lining the intestinal tract. This stimulation of electrogenic chloride secretion, concomitant with an inhibition of sodium absorption, leads to a net fluid secretion into the intestinal lumen. Thus, the endogenous peptides, guanylin, and uroguanylin are involved in the regulation of salt and water transport across the intestinal epithelia. These peptides also regulate CFTR-mediated bicarbonate secretion and inhibit H+ extrusion by the Na+/H+ exchanger in the small bowel. This helps in the regulation of intestinal pH, thus stimulating the digestion and absorption of food components. In addition to maintenance of intestinal fluid balance, guanylin and uroguanylin target the renal tissue, eliciting natriuresis, kaliuresis, and diuresis, along with increasing urinary cGMP levels. Uroguanylin may also influence long-term renal function, since down-regulation of the mRNAs of the Na+/K− ATPase γ-subunit and the chloride channel, ClC-K2, is also observed on uroguanylin administration.
The heat-stable enterotoxin (ST) is a structural and functional homolog of uroguanylin/guanylin. Pathogenic strains of E. coli, and other bacteria that produce ST peptides, cause watery diarrhea as a result of the high levels of fluid–ion secretion elicited by ST binding to GC-C present on intestinal epithelial cells. ST is being considered as a vaccine target to combat enterotoxigenic E. coli, of which some strains are endemic in developing nations. Compared to ST, the endogenous peptides are less potent in stimulating fluid–ion secretion, since the affinity of guanylin and uroguanylin for GC-C is 100-fold and 10-fold lower than ST respectively. ST peptides thus represent a form of molecular mimicry wherein enterotoxigenic E. coli exploit normal intestinal physiology for their dissemination.
Recent reports have identified guanylyl cyclase D (GC-D) as an additional receptor for guanylin and uroguanylin. This less characterized peptide receptor has a domain organization similar to that of GC-C, consisting of an extracellular ligand binding domain, a single transmembrane spanning domain, followed by a kinase homology domain linked to a guanylyl cyclase domain. However unlike GC-C, which is expressed in the intestinal epithelia, GC-D is exclusively expressed in a few neurons of the olfactory epithelia. These cells respond to uroguanylin/guanylin by generating action potentials, probably by elevating intracellular levels of cGMP. Therefore, in addition to a role for uroguanylin and guanylin as hormonal modulators of fluid and electrolyte secretion, there may be other physiological functions for the guanylin family of cGMP-regulating peptides, some of which are discussed below.
Apart from maintaining fluid balance in the vertebrate intestine, uroguanylin is also involved in the regulation of kidney function and maintenance of sodium ion balance in the body. Both effects prevent the development of hypernatremia in response to a high oral salt load. Intravenous application of uroguanylin in mice stimulated Na+, K+, and water excretion in the urine, suggesting that uroguanylin, which is also expressed in the kidney, could serve in an endocrine axis that connects the gastrointestinal tract with the kidney for maintenance of ion balance. Thus, uroguanylin has both local intestinal (paracrine) and endocrine functions, forming a potential enteric–renal link to coordinate salt ingestion with natriuresis. In support of this evidence, it was observed that mice lacking the uroguanylin gene have increased blood pressure and an impaired capacity to excrete Na+ in the urine when salt loads are administered orally. However, intravenous administration of NaCl to uroguanylin knock-out mice elicits natriuresis equivalent to that of wild-type animals. Increased dietary intake of NaCl results in increased uroguanylin expression in the intestine and kidney, implicating both endocrine and paracrine/autocrine actions of uroguanylin in regulation of tubular signaling mechanisms that govern renal sodium transport.
A recent report has suggested that circulating plasma prouroguanylin, the precursor of uroguanylin, may mediate entero-renal signaling. Prouroguanylin is released by the enteroendocrine cells of the intestine in response to a salty meal and is converted to uroguanylin in the kidney, thereby eliciting “postprandial-natriuresis”. This is in line with a report that a high salt diet primes the kidney for an enhanced response to uroguanylin.
GC-C knock-out mice have normal blood pressure and renal sodium excretion, but do not exhibit intestinal secretion in response to ST peptides and uroguanylin/guanylin. Moreover, when uroguanylin, guanylin, or ST peptides are administered intravenously to GC-C knock-out mice, they elicit saluretic and diuretic responses, quantitatively equal to that of wild-type mice. Based on the independent phenotypes of uroguanylin and GC-C knock-out mice, it can be suggested that regulation of renal sodium transport is not mediated by GC-C, but through a receptor for uroguanylin whose identity is as yet unknown, and may be coupled to a G-protein.
The neurons of main olfactory epithelia (MOE) are responsible for sensing a myriad of odors. Canonical olfactory sensory neurons act through odorant receptors and generation of cyclic AMP (cAMP), which binds cyclic nucleotide gated (CNG) channels leading to neuronal membrane depolarization. However, recent research has shown that the cAMP-mediated excitatory pathway is not the lone signaling pathway operating in the MOE. A sub-set of these neurons which express GC-D are suspected to transduce the signal of olfaction in a cAMP-independent manner, as opposed to that seen in the rest of the olfactory epithelia. These cells are devoid of the cAMP signaling machinery involving the odorant receptors, namely, Gα olf, type III adenylyl cyclase, the cAMP-dependent phosphodiesterase (PDE4A) and the cAMP-responsive CNG channel subunits, CNGA2 and CNGB1b. On the other hand, these cells express a cGMP-specific CNG channel subunit CNGA3, and a cGMP-dependent phosphodiesterase (PDE2) in addition to GC-D, highlighting the role of cGMP in the physiology of these neurons. The axons of these GC-D neurons impinge on the “necklace glomeruli” which reside between the main and the accessory olfactory bulb of mice.
Through extensive gene-targeting studies in mice, Leinders-Zufall et al. (2007) demonstrated that these neurons respond to uroguanylin and guanylin in a cGMP-dependent manner to induce formation of action potentials in the MOE. Response to these urinary peptides is specific to the GC-D neurons, and the presence of GC-D has been shown to be crucial for maintenance of normal afferent activity, as well as basal activity, of the necklace glomeruli. GC-D knock-out mice develop the necklace glomeruli but do not respond to the peptide hormones, and have low afferent activity in these neurons. The GC-D neurons express uroguanylin, which can act in an autocrine/paracrine manner, but this stimulus is insufficient to maintain normal afferent activity in these cells which requires stimuli from the external environment. Therefore, uroguanylin may also act as a social signal and communicate information about food. Uroguanylin levels in the urine rise postprandially, and this may translate to specific chemosensory cues about availability or quantity of food present in the environment. Recent evidence shows that GC-D containing neurons can also detect and respond to CO 2 and bicarbonate which are volatile signals. Thus, a sub-population of the MOE responds to urinary uroguanylin and guanylin and forms a unique cGMP-dependent chemodetection system.
Binding of guanylin and uroguanylin to GC-C in the intestinal epithelial cell results in an increase in cGMP levels. Intracellular cGMP levels are reduced by the action of PDE5, which cleaves cGMP to form 5′-GMP. Cyclic GMP can act directly on CNG channels to increase cellular Ca 2+ levels, resulting in colon cell cytostasis. This process is attenuated by the action of cis-l-diltiazem (L-DLT), a CNG channel inhibitor. The tyrosine kinase c-src which is frequently found to be activated in colorectal carcinomas, phosphorylates and inhibits GC-C activity, thereby reducing the anti-tumorigenic effects induced by guanylin/uroguanylin/ST peptides. In olfactory epithelia, uroguanylin/guanylin is recognized by GC-D expressed in a sub-set of neurons and evoke action potentials. These neurons also fire in response to CO2. Hydrolysis of cGMP in these cells is thought to be mediated by PDE2. The renal effects of uroguanylin have been detailed in an earlier review, and are not shown in this figure.
The intestinal epithelium undergoes waves of proliferation, migration, differentiation, and apoptosis driven by multipotent stem cells. Cyclic GMP has emerged as an important regulator of this process, although the molecular mechanisms mediating this activity are still not clear. The cGMP signal transduction pathway activated by guanylin and uroguanylin appears to help in regulating the turnover of epithelial cells, and maintenance of homeostasis of the intestinal mucosa. The expression of uroguanylin and guanylin is markedly reduced in colon carcinoma, in stark contrast to GC-C, whose expression remains comparable to that seen in normal colonic mucosa. This has led to the emergence of GC-C as a marker for metastatic colon carcinoma.
